HORNBILL: A First-in-Human Phase I/IIa Study of the Safety, Tolerability, and Early Pharmacodynamics of BI 764524 for Diabetic Macular Ischemia

HORNBILL: A First-in-Human Phase I/IIa Study of the Safety, Tolerability, and Early Pharmacodynamics of BI 764524 for Diabetic Macular Ischemia

Objective: To report safety and early pharmacodynamic results from a first-in-human trial of intravitreal (IVT) anti-semaphorin 3A antibody in participants with diabetic macular ischemia (DMI). Design: HORNBILL, a phase I/IIa study of BI 764524, comprised a nonrandomized, open-label, uncontrolled, s...

Full description

Saved in:
Bibliographic Details
Main Authors: Quan Dong Nguyen, MD, MSc, Chirag Jhaveri, MD, Maged Habib, MD, Yasir J. Sepah, MBBS, Khaled Nassar, MD, PhD, Bartlomiej Krawczyk, PhD, Gudrun Simons, PhD, Andrea Giani, MD, Elizabeth Pearce, PhD, Martin Gliem, MD, Mohamed Ahmed, MBBCh, MD, Sobha Sivaprasad, DM
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:Ophthalmology Science
Subjects:
Diabetic retinopathy
Sema3A
First-in-human
Retinal nonperfusion
Ischemia
Online Access:http://www.sciencedirect.com/science/article/pii/S266691452500079X
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

http://www.sciencedirect.com/science/article/pii/S266691452500079X

Similar Items